Shares of AstraZeneca plc (LON:AZN) have earned a consensus recommendation of “Hold” from the twenty-two brokerages that are covering the stock, reports. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is GBX 5,057.40 ($67.08).

A number of brokerages recently commented on AZN. Liberum Capital restated a “buy” rating and set a GBX 4,800 ($63.67) target price on shares of AstraZeneca plc in a report on Tuesday, September 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a GBX 5,600 ($74.28) price target on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 4,550 ($60.35) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Thursday, August 31st. Jefferies Group LLC lifted their price target on shares of AstraZeneca plc from GBX 4,350 ($57.70) to GBX 4,800 ($63.67) and gave the company a “hold” rating in a report on Monday, September 11th. Finally, Deutsche Bank AG reissued a “buy” rating and set a GBX 5,700 ($75.61) price objective on shares of AstraZeneca plc in a research report on Friday, July 28th.

In related news, insider Nazneen Rahman purchased 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($57.97) per share, for a total transaction of £1,704.30 ($2,260.64).

AstraZeneca plc (LON AZN) opened at 5077.00 on Wednesday. The company’s market capitalization is GBX 64.27 billion. The company’s 50-day moving average is GBX 4,692.03 and its 200 day moving average is GBX 4,893.11. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

The business also recently announced a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were paid a dividend of GBX 68.90 ($0.91) per share. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc (AZN) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with's FREE daily email newsletter.